83
65
Growth Score
-9 pts
Heat Score
11 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
198681
CMTA is a community-led, non-profit organization that fosters the advancement of innovative therapies for Charcot-Marie-Tooth disease (CMT).
- Suzanne Bruhn: CEOPast Role: Tiaki Therapeutics, CEO and President
- Katherine Forsey: Chief Research Officer
About the Company
The CMTA is aggressively pursuing treatments and a cure for all types of CMT. Since launching the Strategy to Accelerate Research (STAR) in 2008, the CMTA has been working with preeminent researchers, clinicians, patients and institutions in the global inherited neuropathy community to capitalize on breakthroughs in genetics. The CMTA has made
unprecedented progress toward therapies for virtually almost all types of CMT. Since the inception of STAR, the CMTA has financed more than 100 projects and committed over $23.5 million in research. Thanks to support from our donors, STAR continues to gain momentum and the promise of breakthroughs is imminent.
